CCP
AXDX icon

Cardan Capital Partners’s Accelerate Diagnostics AXDX Stock Holding History

Cardan Capital Partners’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,367
Closed -$811K – 184
2019
Q3 		$811K Buy
+4,367
New +$844K 0.12% 114

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
ArrowMark Colorado Holdings
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Cardan Capital Partners's AXDX Position: Q4 2019 in Review

Cardan Capital Partners sold out of Accelerate Diagnostics (AXDX) in Q4 2019, closing a stake of 4,367 shares — an estimated $811K sold.

Cardan Capital Partners first reported a position in AXDX in Q3 2019 and held it in 1 quarter. The position peaked at $811K in Q3 2019. 109 funds tracked by Wall St. Rank hold AXDX as of Q4 2019.

  • Cardan Capital Partners reported no remaining Accelerate Diagnostics position as of Q4 2019 after selling out during the quarter.
  • Cardan Capital Partners sold 4,367 Accelerate Diagnostics shares in Q4 2019, an estimated $811K.
  • Cardan Capital Partners first reported a position in Accelerate Diagnostics in Q3 2019 and held it in 1 quarter.
  • Cardan Capital Partners's Accelerate Diagnostics position peaked at $811K in Q3 2019.
  • 109 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2019.

Based on Cardan Capital Partners's 13F filing for Q4 2019, filed 30 Jan 2020.